NTRK1 and adenocarcinoma: According to this study, potentially druggable mutations were discovered in 20% of CUPs and, of note, alterations in the receptor tyrosine kinase (RTK)/Ras signaling pathway were more frequently detected in adenocarcinoma versus non-adenocarcinoma CUPs (72% versus 39%, p < 0.001) [153].